New York, New York--(Newsfile Corp. - June 16, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.
Class Period: April 24, 2020 and April 16, 2021
Lead Plaintiff Deadline: June 18, 2021
Learn more about your recoverable losses in EBS:
The filed complaint alleges that Emergent Biosolutions Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.
Shareholders have until June 18, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
For additional information about the EBS lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/87839